Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic HER2 -Mutant Non–Small Cell Lung Cancer
JCO Precision Oncology · 2026-06 · 10 (6)
DOI: 10.1200/po-25-01272 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift JCO Precision Oncology, 2026-06. Verfasst von Christine M Lovly und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Erb-b2 Receptor Tyrosine Kinases, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE This observational study assessed the real-world characteristics, treatments, and outcomes of US patients with HER2 -mutant advanced non–small cell lung cancer (NSCLC) overall and according to HER2 mutation type (tyrosine kinase domain [TKD] and non-TKD). METHODS Deidentified data were extracted for patients with advanced/metastatic NSCLC from the Flatiron Health-Foundation Medicine NSCLC Clinico-Genomic Database. Patients with oncogenic HER2 mutations were included. The primary objectives were to assess the prevalence of HER2 mutations and coaberrations, treatment patterns, and real-world overall survival (OS). RESULTS Overall, 559/14,768 (3.8%) patients had HER2 mutations; 262 (1.8%) were oncogenic. Patients with oncogenic TKD mutations (n = 197) were more frequently younger, female, and never-smokers than those with oncogenic non-TKD mutations (n = 65) and had fewer oncogenic coaberrations. Among patients with oncogenic HER2 mutations who underwent first-line treatment (n = 193), most received platinum-based chemoimmunotherapy (30.5%) or chemotherapy alone (27.9%); 119 patients (61.7%) received second-line treatment. Median OS after first and second lines of treatment was 13.5 months (95% CI, 11.6 to 16.9) and 11.1 months (95% CI, 9.2 to 13.6), respectively. Median OS with first-line platinum-based chemoimmunotherapy was 21.1 (95% CI, 12.2 to NA) and 11.7 months (95% CI, 8.3 to NA) in patients with TKD/non-TKD mutations, respectively, and median OS with platinum-based chemotherapy alone was 9.1 (95% CI, 5.7 to 16.0) and 17.3 (95% CI, 13.6 to NA) months, respectively. CONCLUSION NSCLC patients with oncogenic TKD HER2 mutations had different characteristics and genetic features than patients with non-TKD mutations. Real-world outcomes with first- and second-line standard-of-care treatment were suboptimal, highlighting the need for new treatment options for patients with advanced HER2 -mutant NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA.
- Fred Hutchinson Cancer Center, University of Washington, Seattle, WA.
- Division of Hematology and Oncology, Department of Medicine, University of California Irvine Medical Center, Orange County, CA.
- Department of Medicine, University of Colorado Cancer Center, Aurora, CO.
- Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT.
- Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.
ORCID-Profile: Christine M Lovly, Misako Nagasaka, Tejas Patil, Kathryn Evans, Xiuning Le
Zitieren
APA
Lovly, C. M., Baik, C., Nagasaka, M., Patil, T., Maruti, S. S., Stanhope, S., Kaya, N. A., Herbertz, S., Nordstrom, B., Evans, K., & Le, X. (2026). Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic HER2 -Mutant Non–Small Cell Lung Cancer. JCO Precision Oncology, 10(6). https://doi.org/10.1200/po-25-01272
Vancouver
Lovly CM, Baik C, Nagasaka M, Patil T, Maruti SS, Stanhope S, et al. Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic HER2 -Mutant Non–Small Cell Lung Cancer. JCO Precision Oncology. 2026;10(6). doi:10.1200/po-25-01272
BibTeX
@article{Lovly2026,
author = {Lovly, Christine M and Baik, Christina and Nagasaka, Misako and Patil, Tejas and Maruti, Sonia S and Stanhope, Stephen and Kaya, Neslihan A and Herbertz, Stephan and Nordstrom, Beth and Evans, Kathryn and Le, Xiuning},
title = {Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic HER2 -Mutant Non–Small Cell Lung Cancer},
journal = {JCO Precision Oncology},
year = {2026},
volume = {10},
number = {6},
doi = {10.1200/po-25-01272}
}
EUVIMED